Amazines Free Article Archive
www.amazines.com - Sunday, November 18, 2018
Read about the most recent changes and happenings at Amazines.com
Log into your account or register as a new author. Start submitting your articles right now!
Search our database for articles.
Subscribe to receive articles emailed straight to your email account. You may choose multiple categories.
View our newest articles submitted by our authors.
View our most top rated articles rated by our visitors.
* Please note that this is NOT the ARTICLE manager
Add a new EZINE, or manage your EZINE submission.
Add fresh, free web content to your site such as newest articles, web tools, and quotes with a single piece of code!
Home What's New? Submit/Manage Articles Latest Posts Top Rated Article Search
Google
Subscriptions Manage Ezines
CATEGORIES
 Article Archive
 Advertising (133268)
 Advice (160760)
 Affiliate Programs (34733)
 Art and Culture (73638)
 Automotive (145514)
 Blogs (75003)
 Boating (9841)
 Books (17129)
 Buddhism (4122)
 Business (1328009)
 Business News (426289)
 Business Opportunities (366242)
 Camping (10948)
 Career (72746)
 Christianity (15834)
 Collecting (11636)
 Communication (115047)
 Computers (241935)
 Construction (38968)
 Consumer (49637)
 Cooking (17056)
 Copywriting (6567)
 Crafts (18210)
 Cuisine (7533)
 Current Affairs (20371)
 Dating (45768)
 EBooks (19684)
 E-Commerce (48190)
 Education (185103)
 Electronics (83429)
 Email (6389)
 Entertainment (159780)
 Environment (28928)
 Ezine (3038)
 Ezine Publishing (5443)
 Ezine Sites (1552)
 Family & Parenting (110876)
 Fashion & Cosmetics (196377)
 Female Entrepreneurs (11840)
 Feng Shui (130)
 Finance & Investment (310214)
 Fitness (105794)
 Food & Beverages (62814)
 Free Web Resources (7936)
 Gambling (30211)
 Gardening (25061)
 Government (10515)
 Health (629004)
 Hinduism (2156)
 Hobbies (44026)
 Home Business (91542)
 Home Improvement (251220)
 Home Repair (46094)
 Humor (4802)
 Import - Export (5443)
 Insurance (45082)
 Interior Design (29541)
 International Property (3485)
 Internet (190953)
 Internet Marketing (146278)
 Investment (22822)
 Islam (1168)
 Judaism (1357)
 Law (80449)
 Link Popularity (4592)
 Manufacturing (20798)
 Marketing (98724)
 MLM (14136)
 Motivation (18208)
 Music (26996)
 New to the Internet (9475)
 Non-Profit Organizations (4048)
 Online Shopping (129604)
 Organizing (7796)
 Party Ideas (11854)
 Pets (38084)
 Poetry (2234)
 Press Release (12667)
 Public Speaking (5620)
 Publishing (7522)
 Quotes (2407)
 Real Estate (126601)
 Recreation & Leisure (95236)
 Relationships (87425)
 Research (16151)
 Sales (80293)
 Science & Technology (110123)
 Search Engines (23445)
 Self Improvement (153065)
 Seniors (6220)
 Sexuality (35933)
 Small Business (49274)
 Software (82914)
 Spiritual (23447)
 Sports (116456)
 Tax (7657)
 Telecommuting (34073)
 Travel & Tourism (306828)
 UK Property Investment (3117)
 Video Games (13420)
 Web Traffic (11723)
 Website Design (56775)
 Website Promotion (36554)
 World News (1000+)
 Writing (35754)
Author Spotlight
SUNNY NASH

Sunny Nash is the award-winning American author of Bigmama Didn’t Shop At Woolworth’s, recognized by...more
ALFRED MEARS

Former English Teacher; Musician (20+ years); Freelance Writer ...more
ARSLAN EJAZ

Arslan Ejaz Rao has been researching and writing about news stories, information and trends for the ...more
ALEN OWEN

I am an essay writer with vast experience in data analysis, PowerPoint writing and research paper ed...more
SAAD KHAN

my name is Saad Khan and i write to give some detailed information on things which matter to the mas...more


AV-951 IN THE TREATMENT OF ANGIOGENIC by Calder Qimat






Article Author Biography
AV-951 IN THE TREATMENT OF ANGIOGENIC by
Article Posted: 12/15/2011
Article Views: 1130
Articles Written: 131
Word Count: 740
Article Votes: 0
AddThis Social Bookmark Button

AV-951 IN THE TREATMENT OF ANGIOGENIC


 
Health
ANGIOGENESIS AND AV-951:

Angiogenesis as a process is very crucial for the progression of tumors. Not only cells proliferate uncontrollably in cancers, they require a better vascular system to support these new and upcoming cells. Hence the development of anti-angiogenesis compounds is seen as an attractive approach that can deal with one facet of tumor biology successfully. The most commonly linked pathway to angiogenesis is Vascular Endothelial Growth Factor (VEGF) pathway and the inhibition of this particular pathway at its receptor level has yielded promising results. There are many VEGF receptor (VEGFR) inhibitors that are being developed and tested in preclinical models and clinical trials and AV-951 VEGFR inhibitor is one of them that has shown potent inhibition of angiogenesis and tumor progression [1]. The best part of AG-951 pharmacology is that apart from VEGFR inhibition, its potency to inhibit c-Kit and PDGFR phosphorylation is also well documented.

AG-951 PHARMACOLOGY AND PROPERTIES:

AG-951 suppliers sell it under the brand name of Tivozanib also, and it is being developed by Aveo pharmaceutical company. The oral AV-951 PDGFR inhibitor is priced little high and AV-951 price for a 10 mg vial is around $200 and one can buy AV-951 easily for research and laboratory uses. AV-951 structure shows that is a quinoline urea derivative. AV-951 solubility is not found in water and ethanol but in DMSO, a 5 mg/ml solution can be made. When stored at -20oC, AV-951 stability is for 2 years. AV-951 IC50 against VEGFR-1, VEGFR-2, and VEGFR-3 tyrosine kinase inhibition is 30 nM, 6.5 nM, and 15 nM, respectively. The IC50 values of AV-951 c-Kit inhibitor are 40 nM, 49 nM, 24 nM, 78 nM, and 78 nM for PDGFR-a, PDGFR-ß, EphB2, c-Kit, and Tie2 tyrosine kinases, respectively.

THERAPEUTIC TESTING OF AV-591 AT VARIOUS LEVELS:

The in vitro preclinical studies on AV-951 show its efficacy on blocking the proliferation and migration potential of endothelial cells, and in vivo studies with human tumor xenografts confirmed the same. AV-951 produced minimal toxicity in cancer patients and is under clinical trials for the treatment of renal cell carcinoma (RCC) and non-small cell lung (NSCL) carcinoma as a single agent, and in colorectal, breast, and other gastrointestinal tumors (GISTs) as a combination therapy. In athymic rat xenograft in vivo models of colon, hepatic, breast, lung, prostate, ovarian, and pancreatic tumors, AV-591 showed potent tumor growth inhibition [2].

The oral dose of AV-591 was decided in a clinical trial on patients with solid tumors from a study assessing its safety, pharmacodynamics and pharmacokinetics [3] after it showed success in treating solid tumors in athymic murine models [4]. 25% overall response rate and a progression-free survival of an year was observed in advanced renal cell carcinoma (RCC) patients upon treatment with AV-951 in a phase II clinical trial [4]. Apart from the success of AV-951 clinical trials, it has been patented for renal cell carcinoma (US2011/0118297 A1) patients and by Aveo pharmaceuticals for treatment of tumors (patent no US 7,736,861 B1). Various ongoing clinical trials involving AV-951 include studies from Aveo pharmaceuticals where its given in combination with Capecitabine A to solid tumor patients enrolled for a phase Ib trial assessing its maximum-tolerated dose (MTD) in these and in breast and colon cancer patients (NCT01306630). Another study from Aveo checks the synergistic effect of its combination with the traditional chemotherapeutic drug FOLFOX6 in patients suffering from advanced colorectal cancer (CRC) and gastrointestinal cancers in a phase I clinical trial (NCT00660153). Aveo is also checking its efficiency in renal cell carcinoma patients undergoing a phase 2 trial (NCT00502307).

REFERENCS:

1. Campas, C.e.a., Tivozanib. Drugs of the Future, 2009.

2. Nakamura, K., et al, KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res., 2006.

3. Eskens, F.E.e.a., Biological and Clinical Activity of Tivozanib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4 Week on, 2 Week off Schedule in Patients With Advanced Solid Tumors. Clin Cancer Res, 2011.

4. De Luca, A.a.N., N., Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs, 2010.

Buy from the biotech company which is well known by scientists and drug discovery researchers worldwide for novel kinase inhibitors. Vist us to get more information regarding life reagents like Chemical Libraries, kinase inhibitor, kinase inhibitors, parp inhibitor, parp inhibitors more.

Related Articles - Chemical Libraries, kinase inhibitor, kinase inhibitors, parp inhibitor, parp inhibitors,







Email this Article to a Friend!

Receive Articles like this one direct to your email box!
Subscribe for free today!

 Rate This Article  
Completely useless, should be removed from directory.
Minimal useful information.
Decent and informative.
Great article, very informative and helpful.
A 'Must Read'.

 

Do you Agree or Disagree? Have a Comment? POST IT!

 Reader Opinions 
Submit your comments and they will be posted here.
Make this comment or to the Author only:
Name:
Email:
*Your email will NOT be posted. This is for administrative purposes only.
Comments: *Your Comments WILL be posted to the AUTHOR ONLY if you select PRIVATE and to this PUBLIC PAGE if you select PUBLIC, so write accordingly.
 
Please enter the code in the image:



 Author Login 
LOGIN
Register for Author Account

 

Advertiser Login

 

ADVERTISE HERE NOW!
   Limited Time $60 Offer!
   90  Days-1.5 Million Views  

 

Great Paranormal Romance

World News


STEPHEN BYE

Steve Bye is currently a fiction writer, who published his first novel, ‘Looking Forward Through The...more
GENE MYERS

Author of four books and two screenplays; frequent magazine contributor. I have four other books "in...more
SUSAN FRIESEN

Susan Friesen, founder of the award-winning web development and digital marketing firm eVision Media...more
LAURA JEEVES

At LeadGenerators, we specialise in content-led Online Marketing Strategies for our clients in the t...more
JAVIER VBOIX

For the time being just a newbie in the Insurance Industry but a quick learner, soon-to-be expert Ja...more
SANDY FISCHEL

Sandy Fischel is the marketing director at And Above All YOGA, a wholly owned division of The Fische...more
MICHAEL BRESCIANI

Rev Bresciani is the author of two Christian books. One book is an important and concisely written b...more
CHRISTOPHER EVANS

Christopher is based in the U.K. and is the author and founder of Critical Eye. ...more
STEVERT MCKENZIE

Stevert Mckenzie, Travel Enthusiast. ...more
MICHAEL MIFSUD

Michael Mifsud was a House of Commons Commonwealth correspondent at the age of 16. He published Brit...more

HomeLinksAbout UsContact UsTerms of UsePrivacy PolicyFAQResources
Copyright © 2018, All rights reserved.
Some pages may contain portions of text relating to certain topics obtained from wikipedia.org under the GNU FDL license